Evidence Updates - Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database including professional commentaries

also:  see PubMed link (abstract w/o commentary) to abstract

BACKGROUND: Treatment of cancer is increasingly more effective but is associated with short and long term side effects. Oral side effects remain a major source of illness despite the use of a variety of agents to prevent them. One of these side effects is oral mucositis (mouth ulcers).

abstract: Treatment of bevacizumab-induced hypertension by Amlodipine

Also reference:
NORVASC® (amlodipine besylate) Tablets for Oral Administration

http://www.rxlist.com/norvasc-drug.htm

Mayo Collaboration Finds Source of Breast Drug Side Effect - Drugs.com MedNews (aromatase inhibitors/arthritis/bone pain)

Mayo Collaboration Finds Source of Breast Drug Side Effect

Pharmacogenomic discovery allows for improved cancer therapy

ROCHESTER, Minn. — Mayo Clinic researchers and their international colleagues have discovered genetic variants that lead to severe arthritis for a subset of women when taking aromatase inhibitors to treat their breast cancer. This serious side effect is so painful that many women halt their lifesaving medication. The findings appear today in the online issue of Journal of Clinical Oncology.


Read more: http://www.drugs.com/clinical_trials/mayo-collaboration-finds-source-breast-10214.html#ixzz10seG0Pnb

Diffusion-weighted Imaging of Peritoneal Disease for Noninvasive Staging of Advanced Ovarian Cancer1 — RadioGraphics

EvidenceUpdates - Bevacizumab (Avastin) increases risk for severe proteinuria in cancer patients including professional commentaries

article link:
http://plus.mcmaster.ca/EvidenceUpdates/NewArticles.aspx?Page=1&ArticleID=35795#Data

abstract link:
http://www.ncbi.nlm.nih.gov/pubmed/20538785?dopt=Abstract

Summary- Clinical burden of venous thromboembolism

Conclusions:

Even among high-risk groups it is not possible to identify individuals who will go on to develop VTE, and, therefore, thromboprophylaxis is a recommended component of the management of high-risk patients. Ensuring patients receive safe, effective, easily administered antithrombotic therapy both in hospital and post-discharge, for a sufficient length of time, should be central to any strategy to reduce incident or recurrent VTE and minimise the risk of long-term complications.

CHOP iPhone App Records Side Effects in Clinical Trials | The Children's Hospital of Philadelphia

example as per website

Abstract: Cervical manifestation of a borderline type ovarian cancer with pseudomyxoma peritonei - a case report

Note: mucinous cell type is a cell type found in numerous organs including colon/rectum Abstract: Borderline tumours of the ovary (BOTs) are rare tumour entities that do not show any destructive or invasive growth in the majority of cases, even though they can display characteristics of malignant tumours The mucinous subtype can also originate from the appendix, and ovarian metastases can mimic primary ovarian BOTs, often accompanied by peritoneal manifestation in terms of pseudomyxoma peritonei. In cases where a concomitant appendiceal tumour is present, it may prove difficult to determine the primary tumour. This report describes a special case of BOT with a specific example of the complexity of the differential diagnosis of pseudomyxoma peritonei. Especially the case was simultaneously linked to appendiceal and ovarian cancer. Moreover, this case was exceptional for its unusual manifestation of BOT in the cervix.

(Avastin) Bevacizumab-induced small bowel perforation in a patient with breast cancer without intraabdominal metastases (abstract)

Cardiovascular Safety of VEGF-Targeting Therapies: Current Evidence and Handling Strategies -- Girardi et al., 10.1634/theoncologist.2009-0235 -- The Oncologist

Abstract
Treatment with the angiogenesis inhibitors bevacizumab, sunitinib, and sorafenib as single agents or in combination with conventional chemotherapy is becoming a cornerstone of modern anticancer therapy. However, the potential toxicity of these drugs, mainly to the cardiovascular system, is still being investigated. Patient assessment at baseline, of crucial importance in candidates for treatment, involves the evaluation of risk factors and screening for past or present cardiovascular disease. Strict monitoring of treatment-related adverse effects must be conducted in order to allow the early detection of cardiovascular toxicities and their prompt medication. In the present paper, the most frequent cardiovascular toxicities and their underlying mechanisms are investigated, with a view to providing indications for effective patient management.

Efficacy of lower dose of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer resistant to platinum-based therapy

Conclusions: Lower dose of weekly topotecan was well tolerated in patients with platinum-resistant ovarian or peritoneal cancer at first relapse, with a favourable hematologic profile. Moreover, antitumor activity was similar to that reported for the standard dose of weekly regimen.

2010: Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer : The Lancet Oncology (abstract only)

Note: abstract/full access is by subscription/$$